{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "TPL_1", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-3 16:50:5", "close_timestamp": 1635958205259, "created": "03/11/2021 16:50:06", "department": "Editorial", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-03", "gender": "male", "id": "cd102d8c-9f13-401b-9c28-cca2112aa64b", "open_date_time": "2021-10-3 16:43:16", "open_timestamp": 1635957796812, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "A study from Monash University in Australia has shown that ivermectin, a widely-used parasitic, can kill coronavirus within 48 hours.", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 408447, "what": "A university study in Australia showing that ivermectin can kill coronavirus rapidly", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Monash University researchers; ivermectin", "why": "It shows that a readily available compound can kill coronavirus within 48 hours"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "TPL_1", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-3 16:36:53", "close_timestamp": 1635957413283, "created": "03/11/2021 16:36:54", "department": "Editorial", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-03", "gender": "male", "id": "077b29df-3a92-457d-9eed-69bbbfbf6dd3", "open_date_time": "2021-10-3 16:31:12", "open_timestamp": 1635957072761, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "GlobalData is suggesting potential challenges with Novavax's development of a coronavirus vaccine based on trial data.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 340522, "what": "A perspective on a coronavirus vaccine from Novavax and the challenges it may face", "when_happened": "current_week", "where_location": "USA; Mexico", "who": "Novavax; GlobalData", "why": "Because it relates to the potential efficacy of a coronavirus vaccine in development"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "TPL_1", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-3 16:30:35", "close_timestamp": 1635957035528, "created": "03/11/2021 16:30:37", "department": "Editorial", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-03", "gender": "male", "id": "bd6f9c6c-efe3-4a0f-85fe-f274293a9c64", "open_date_time": "2021-10-3 16:21:46", "open_timestamp": 1635956506696, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "GPs in Australian are being urged to prescribe ivermectin combination therapy to treat coronavirus to help save lives during the pandemic. The therapy comprises zinc and doxycyline. ", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 528832, "what": "Australian GPs being urged to prescribe the drug ivermectin for COVID-19", "when_happened": "current_week", "where_location": "Australia", "who": "Australian GPs", "why": "It suggests a treatment for COVID-19 that is being used by GPs"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "TPL_1", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-3 16:43:7", "close_timestamp": 1635957787491, "created": "03/11/2021 16:43:08", "department": "Editorial", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-03", "gender": "male", "id": "bdfb7213-705a-4848-b471-26d2603126c5", "open_date_time": "2021-10-3 16:37:8", "open_timestamp": 1635957428348, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan has approved the coronavirus combination treatment Ronapreve to treat coronavirus, becoming the first country in the world to do so.", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 359143, "what": "The approval of a COVID-19 combination in Japan", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Japanese regulator; Regeneron; Roche/Chugai", "why": "Because of the need of coronavirus patients in Japan/more widely"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "TPL_1", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-3 17:14:53", "close_timestamp": 1635959693674, "created": "03/11/2021 17:14:55", "department": "Editorial", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-03", "gender": "male", "id": "1e897cc2-4f10-4f95-bf37-ef6874c8a314", "open_date_time": "2021-10-3 17:4:30", "open_timestamp": 1635959070012, "summary": "A series of reports on the activities of Pfizer over a two/three month period in the spring of 2021. These reports cover topics including: the company's development and commercialisation of its coronavirus vaccine Comirnaty; development and regulatory updates on Pfizer's other products across therapy areas and on its collaborations with other companies; the group's financial performance and sales projections; wider strategic development updates at the company, and outside comment/views on Pfizer's activities.", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 623662}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "TPL_1", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-3 17:4:14", "close_timestamp": 1635959054254, "created": "03/11/2021 17:04:16", "department": "Editorial", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-03", "gender": "male", "id": "d4c8f617-b2cc-4673-a62f-f9cd8d93df7f", "open_date_time": "2021-10-3 16:50:19", "open_timestamp": 1635958219204, "summary": "The activities of AstraZeneca over a two/three month period in the spring of 2021, as summarised by a series of news reports. These reports include coverage of the following: the company's development, manufacture and roll-out of a coronavirus vaccine and an ongoing legal dispute with the EU relating to the vaccine; the group's financial performance; trial results and regulatory approvals of other AstraZeneca products; analysis of the performance of the company's chief executive, Pascal Soriot. ", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 835050}}}